139 related articles for article (PubMed ID: 9923558)
1. Fractionated administration of high-dose cyclophosphamide: influence on dose-dependent changes in pharmacokinetics and metabolism.
Busse D; Busch FW; Schweizer E; Bohnenstengel F; Eichelbaum M; Fischer P; Schumacher K; Aulitzky WE; Kroemer HK
Cancer Chemother Pharmacol; 1999; 43(3):263-8. PubMed ID: 9923558
[TBL] [Abstract][Full Text] [Related]
2. Dose escalation of cyclophosphamide in patients with breast cancer: consequences for pharmacokinetics and metabolism.
Busse D; Busch FW; Bohnenstengel F; Eichelbaum M; Fischer P; Opalinska J; Schumacher K; Schweizer E; Kroemer HK
J Clin Oncol; 1997 May; 15(5):1885-96. PubMed ID: 9164199
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of intravenous etoposide in patients with breast cancer: influence of dose escalation and cyclophosphamide and doxorubicin coadministration.
Busse D; Würthwein G; Hinske C; Hempel G; Fromm MF; Eichelbaum M; Kroemer HK; Busch FW
Naunyn Schmiedebergs Arch Pharmacol; 2002 Sep; 366(3):218-25. PubMed ID: 12172704
[TBL] [Abstract][Full Text] [Related]
4. Cyclophosphamide and 4-Hydroxycyclophosphamide/aldophosphamide kinetics in patients receiving high-dose cyclophosphamide chemotherapy.
Anderson LW; Chen TL; Colvin OM; Grochow LB; Collins JM; Kennedy MJ; Strong JM
Clin Cancer Res; 1996 Sep; 2(9):1481-7. PubMed ID: 9816324
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of cyclophosphamide and thiotepa in a conventional fractionated high-dose regimen compared with a novel simplified unfractionated regimen.
Ekhart C; Rodenhuis S; Beijnen JH; Huitema AD
Ther Drug Monit; 2009 Feb; 31(1):95-103. PubMed ID: 19155964
[TBL] [Abstract][Full Text] [Related]
6. Urinary excretion of cyclophosphamide in humans, determined by phosphorus-31 nuclear magnetic resonance spectroscopy.
Joqueviel C; Martino R; Gilard V; Malet-Martino M; Canal P; Niemeyer U
Drug Metab Dispos; 1998 May; 26(5):418-28. PubMed ID: 9571223
[TBL] [Abstract][Full Text] [Related]
7. Validation of urinary excretion of cyclophosphamide as a biomarker of exposure by studying its renal clearance at high and low plasma concentrations in cancer patients.
Hedmer M; Höglund P; Cavallin-Ståhl E; Albin M; Jönsson BA
Int Arch Occup Environ Health; 2008 Jan; 81(3):285-93. PubMed ID: 17579883
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of cyclophosphamide and its metabolites in paediatric patients receiving high-dose myeloablative therapy.
Chinnaswamy G; Errington J; Foot A; Boddy AV; Veal GJ; Cole M
Eur J Cancer; 2011 Jul; 47(10):1556-63. PubMed ID: 21482104
[TBL] [Abstract][Full Text] [Related]
9. Urinary elimination of cyclophosphamide alkylating metabolites and free thiols following two administration schedules of high-dose cyclophosphamide and mesna.
Fleming RA; Cruz JM; Webb CD; Kucera GL; Perry JJ; Hurd DD
Bone Marrow Transplant; 1996 Apr; 17(4):497-501. PubMed ID: 8722345
[TBL] [Abstract][Full Text] [Related]
10. Nonlinear pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide/aldophosphamide in patients with metastatic breast cancer receiving high-dose chemotherapy followed by autologous bone marrow transplantation.
Chen TL; Kennedy MJ; Anderson LW; Kiraly SB; Black KC; Colvin OM; Grochow LB
Drug Metab Dispos; 1997 May; 25(5):544-51. PubMed ID: 9152592
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of high-dose cyclophosphamide for bone marrow transplantation.
Fasola G; Lo Greco P; Calori E; Zilli M; Verlicchi F; Motta MR; Ricci P; Baccarani M; Tura S
Haematologica; 1991; 76(2):120-5. PubMed ID: 1937169
[TBL] [Abstract][Full Text] [Related]
12. Cyclophosphamide pharmacokinetics and dose requirements in patients with renal insufficiency.
Haubitz M; Bohnenstengel F; Brunkhorst R; Schwab M; Hofmann U; Busse D
Kidney Int; 2002 Apr; 61(4):1495-501. PubMed ID: 11918757
[TBL] [Abstract][Full Text] [Related]
13. The effect of busulphan on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite: time interval influence on therapeutic efficacy and therapy-related toxicity.
Hassan M; Ljungman P; Ringdén O; Hassan Z; Oberg G; Nilsson C; Békassy A; Bielenstein M; Abdel-Rehim M; Georén S; Astner L
Bone Marrow Transplant; 2000 May; 25(9):915-24. PubMed ID: 10800057
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of (R)- and (S)-cyclophosphamide and their dechloroethylated metabolites in cancer patients.
Williams ML; Wainer IW; Granvil CP; Gehrcke B; Bernstein ML; Ducharme MP
Chirality; 1999; 11(4):301-8. PubMed ID: 10224657
[TBL] [Abstract][Full Text] [Related]
15. A mechanism-based pharmacokinetic-enzyme model for cyclophosphamide autoinduction in breast cancer patients.
Hassan M; Svensson US; Ljungman P; Björkstrand B; Olsson H; Bielenstein M; Abdel-Rehim M; Nilsson C; Johansson M; Karlsson MO
Br J Clin Pharmacol; 1999 Nov; 48(5):669-77. PubMed ID: 10594468
[TBL] [Abstract][Full Text] [Related]
16. [Pharmacokinetic aspects of oral administration of etoposide].
Tillmann B; Krümpelmann S; Würthwein G; Wagner A; Schulze-Westhoff P; Hempel G; Jürgens H; Boos J
Klin Padiatr; 1998; 210(4):159-64. PubMed ID: 9743946
[TBL] [Abstract][Full Text] [Related]
17. A mechanism-based pharmacokinetic model for the cytochrome P450 drug-drug interaction between cyclophosphamide and thioTEPA and the autoinduction of cyclophosphamide.
Huitema AD; Mathôt RA; Tibben MM; Rodenhuis S; Beijnen JH
J Pharmacokinet Pharmacodyn; 2001 Jun; 28(3):211-30. PubMed ID: 11468938
[TBL] [Abstract][Full Text] [Related]
18. Urinary excretion and pharmacokinetics of acrolein and its parent drug cyclophosphamide in bone marrow transplant patients.
Al-Rawithi S; El-Yazigi A; Ernst P; Al-Fiar F; Nicholls PJ
Bone Marrow Transplant; 1998 Sep; 22(5):485-90. PubMed ID: 9733272
[TBL] [Abstract][Full Text] [Related]
19. The influence of interferon-alpha on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite in patients with multiple myeloma.
Hassan M; Nilsson C; Olsson H; Lundin J; Osterborg A
Eur J Haematol; 1999 Sep; 63(3):163-70. PubMed ID: 10485271
[TBL] [Abstract][Full Text] [Related]
20. Population pharmacokinetics of cyclophosphamide and its metabolites 4-hydroxycyclophosphamide, 2-dechloroethylcyclophosphamide, and phosphoramide mustard in a high-dose combination with Thiotepa and Carboplatin.
de Jonge ME; Huitema AD; van Dam SM; Rodenhuis S; Beijnen JH
Ther Drug Monit; 2005 Dec; 27(6):756-65. PubMed ID: 16306851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]